Prostatype Genomics AB (PROGEN) — Financial Flexibility Index
Prostatype Genomics AB (PROGEN) has a Financial Flexibility Index of -1.15x as of June 2025. Free cash flow of Skr-8.43 Million (operating CF Skr-8.54 Million minus capex Skr114.50K) represents -1% of total liabilities (Skr7.36 Million). Check Prostatype Genomics AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Prostatype Genomics AB Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Prostatype Genomics AB across 8 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Prostatype Genomics AB.
Annual Financial Flexibility Index for Prostatype Genomics AB (2016–2024)
Year-by-year free cash flow to debt coverage for Prostatype Genomics AB. Explore PROGEN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (SEK) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.33x | Skr-36.85 Million | Skr-44.71 Million | Skr8.50 Million | ▼ -417.1% |
| 2023 | -0.84x | Skr-20.58 Million | Skr-29.14 Million | Skr24.55 Million | ▲ +85.5% |
| 2022 | -5.77x | Skr-27.69 Million | Skr-27.69 Million | Skr4.80 Million | ▼ -82.6% |
| 2021 | -3.16x | Skr-13.58 Million | Skr-16.08 Million | Skr4.30 Million | ▼ -15.6% |
| 2020 | -2.73x | Skr-14.69 Million | Skr-14.71 Million | Skr5.37 Million | ▼ -287.4% |
| 2018 | -0.71x | Skr-6.37 Million | Skr-9.63 Million | Skr9.03 Million | ▼ -807.7% |
| 2017 | -0.08x | Skr-1.05 Million | Skr-5.71 Million | Skr13.49 Million | ▲ +96.1% |
| 2016 | -2.01x | Skr-9.60 Million | Skr-9.63 Million | Skr4.79 Million | — |